TCL Archive ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial. September 8, 2006
TCL Archive NCI Planning To Switch Drug Development Emphasis From Compound To Human Cancer Oriented Strategy October 26, 1984
TCL Archive Two Phase II Ibrutinib Studies Presented to EHA Demonstrate Efficacy as a Monotherapy July 26, 2013
